Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Mar 30, 2010

Premium

Steve Lincoln has joined Complete Genomics as vice president of scientific applications. He previously served as vice president of informatics at Affymetrix, executive vice president of product development and CSO of InforMax, and vice president of bioinformatics R&D at Incyte.


Frank Pitzer has been appointed as CEO of Roche NimbleGen, which is part of Roche Applied Science, a unit of Roche Diagnostics. Most recently, he was head of divisional quality and regulatory affairs at Roche Diagnostics. Pitzer holds a PhD in biology from the Max Planck Institute for Biochemistry.


Dian Donnai has won the 2010 March of Dimes/Colonel Harland Sanders award for her lifetime achievement in the field of genetic sciences. She is a professor of medical genetics at the University of Manchester in the UK and the president of the European Society for Human Genetics. She is also the clinical head of St. Mary's Hospital in the Central Manchester University Hospitals NHS Trust, which includes the Genetic Medicine Center. Donnai is known for her research on rare genetic diseases, such as Williams syndrome.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.